Society for Translational Oncology navigateright Episode
Monitoring ctDNA is a promising new approach to personalized cancer medicine that may provide real-time information about the evolution of tumors. We evaluated how changes in ctDNA predicted response to treatment across metastatic gastrointestinal cancer patients on treatment and compared ctDNA to standard tumor markers. Longitudinal ctDNA assessment both in the curative and metastatic settings may provide insight into the dynamic changes due to treatment.
Video Overview: https://youtu.be/z2v2dlvUmXs
Aparna Raj Parikh, MD
Massachusetts General Hospital
STO gratefully acknowledges educational grants in partial support of this activity from:
Novartis Pharmaceuticals Corp.